



Total Syntheses of HMP-Y1, Hibarimicinone, and HMP-P1

Citation

Liau, Brian B., Benjamin C. Milgram, Matthew D. Shair. 2012. Total syntheses of HMP-Y1, hibarimicinone, and HMP-P1. *Journal of the American Chemical Society* 134(40): 16765–16772.

Published Version

doi:10.1021/ja307207q

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:9639969>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Total Syntheses of HMP-Y1, Hibarimicinone, and HMP-P1

Brian B. Liao, Benjamin C. Milgram, and Matthew D. Shair*

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States

ABSTRACT: Total syntheses of HMP-Y1, atrop-HMP-Y1, hibarimicinone, atrop-hibarimicinone, and HMP-P1 are described using a two-directional synthesis strategy. A novel benzyl fluoride Michael–Claisen reaction sequence was developed to construct the complete carbon skeleton of HMP-Y1 and atrop-HMP-Y1 via a symmetrical, two-directional, double annulation. Through efforts to convert HMP-Y1 derivatives to hibarimicinone and HMP-P1, a biomimetic mono-oxidation to desymmetrize protected HMP-Y1 was realized. A two-directional unsymmetrical double annulation and biomimetic etherification were developed to construct the polycyclic and highly-oxidized skeleton of hibarimicinone, atrop-hibarimicinone, and HMP-P1. The use of a racemic biaryl precursor allowed for the synthesis of both hibarimicinone atropisomers and provides the first confirmation of the structure of atrop-hibarimicinone. Additionally, this work documents the first reported full characterization of atrop-hibarimicinone, HMP-Y1, atrop-HMP-Y1, and HMP-P1. Lastly, a pH-dependent rotational barrier about the C2–C2' bond of hibarimicinone was discovered, which provides valuable information necessary to achieve syntheses of the glycosylated congeners of hibarimicinone.

INTRODUCTION

Background. Hibarimicins A–G are complex pseudo-dimeric type-II polyketides isolated from the culture broth of the rare actinomycete *Microbispora rosea* subsp. *hibaria* TP-A0121.¹ These metabolites inhibit proliferation and induce differentiation of numerous human cancer cell lines. In particular, hibarimicin B (**1**, Figure 1), which is identical to angelmicin B,^{1b,c} has the most potent anti-proliferative activity in HL-60 cells (IC_{50} = 58 nM).^{1h} The cellular target and biological mechanism of action of **1** remain





Figure 1. Structure of hibarimicin B (**1**).

undetermined. The hibarimicins are amongst the most complex and largest type-II polyketides known. Hibarimicins A–G share an unprecedented highly-oxidized aglycon, hibarimicinone (**2a**, Scheme 1). The C_2 -symmetry of **2a** is broken by oxidation of the B-, C-, and D-rings relative to the G-, F-, and E-rings, respectively. More specifically, the B-ring contains a cyclic ether bridging C8' and C13', the C-ring contains a hydroxyl group at C6', and the D-ring is a quinone. Furthermore, **2a** exhibits axial chirality about its highly congested C2–C2' bond and is isolated as a single atropisomer.^{1i,2} Altogether, the hibarimicins and hibarimicinone (**2a**) are challenging targets that have resisted total synthesis³ until earlier this year when Tatsuta et al. reported the first total synthesis of **2a**.⁴ Herein, we report enantioselective total syntheses of hibarimicinone (**2a**) and atrop-hibarimicinone (**2b**), and the first total syntheses of the biosynthetically related natural product aglycons HMP-Y1 (**3a**), atrop-HMP-Y1 (**3b**) and HMP-P1 (**6**) (Scheme 1).

Scheme 1. Proposed Biosynthetic Conversion of HMP-Y1 (**3a**) to Hibarimicinone (**2a**) and HMP-P1 (**6**)




Biosynthesis Hypothesis. Mutagenesis of *Microbispora rosea* subsp. *hibaria* TP-A0121 led to the identification of novel metabolites, including HMP-Y1 (**3a**), HMP-P1 (**6**), and their glycosylated derivatives (Scheme 1).^{1f} Through ¹³C-acetate labeling studies, it was discovered that C_2 -symmetric **3a** is a precursor to **2a**, which is subsequently glycosylated to yield hibarimicins A–G. Ostensibly,

this conversion (**3a** → **2a**) proceeds by breaking the C₂-symmetry of **3a** via oxidation of the B-, C-, and D-rings and demethylation of the C4'-OMe methyl group. We postulated that a single desymmetrizing oxidation of the C-ring of **3a** to hypothetical quinone **4** would be sufficient to relay oxidation to the B- and D-rings. This could be achieved via (1) tautomerization of quinone **4** to C8'-*ortho*-quinone methide **5** with subsequent oxy-Michael addition of the C13'-OH to install the B-ring cyclic ether, (2) re-oxidation of the C-ring, and (3) transposition of the C-ring quinone to the D-ring with concomitant demethylation to give **2a**. HMP-P1 (**6**) arises from **2a** via cyclization of C1-OH onto C3' of the D-ring quinone and subsequent expulsion of methanol.^{1f}

Results and Discussion

Scheme 2. Biosynthesis-Inspired Retrosynthesis Analysis of HMP-Y1 (**3a**), Hibarimicinone (**2a**), and HMP-P1 (**6**)




Synthesis Plan. Inspired by our proposed biosynthetic relay oxidation scheme, we envisioned that a similar set of biomimetic retrosynthetic disconnections could simplify **2a** to two plausible precursors, C₂-symmetric octacycle **7** and pseudo-C₂-symmetric octacycle **8** (Scheme 2). Targeting **7** was attractive for two reasons: (1) global deprotection would yield HMP-Y1 (**3a**) and (2) it would allow direct assessment of the feasibility of a biomimetic mono-oxidation to access a quinone analogous to **4**. In contrast to **7**, the C₂-symmetry of **8** is perturbed by the presence of a benzyl group⁵ and the C6'-OH (both highlighted in red), the latter of which would facilitate chemoselective C-ring oxidation to a quinone. The most noteworthy feature shared by both **7** and **8** is the degeneracy of the AB- and HG-ring systems that result from the retrosynthetic excision of the B-ring cyclic ether bond. Next, it was envisioned that both octacyclic systems could be constructed in a single operation via a two-directional double annulation,⁶ where the dianion of biaryl **10** would react with two equivalents of the AB-/HG-enone (+)-**9**. The use of a symmetric biaryl annulation donor would lead to **7** whereas the employment of an unsymmetrical variant, with additional oxidation at C6', would result in **8**. Both of these strategies are convergent and circumvent the need to construct the hindered C2-C2' bond at a late stage. Efforts by the Roush group to form the C2-C2' bond in simple model systems via cross-coupling were met with difficulty.^{3d} At the outset of our study, the configuration of the stereochemical axis about the C2-C2' bond of hibarimicinone (**2a**) was ambiguous.¹¹ Consequently, we elected to proceed with race-

mic biaryl annulation donor **10** to prepare and characterize both atropisomers of HMP-Y1 (**3a**) and hibarimicinone (**2a**).

Synthesis of the AB-/HG-Enone (+)-9**.** We previously reported a gram-scale enantiospecific synthesis of the AB-/HG-ring system corresponding to the unnatural enantiomer of **2a**.³ⁱ The AB-/HG-enone (+)-**16** (Scheme 3), with stereochemistry corresponding to the natural enantiomer of **2a**, was prepared from key intermediate cyclohexenone (+)-**15** following an analogous series of diastereoselective transformations. Notably, both enantiomers of (+)-**15** were accessed from α-D-methyl-glucopyranoside by taking advantage of its latent C₂-symmetry. The AB-/HG-enone synthesis commenced with AcOH-mediated deprotection of benzylidene acetal **11** followed by selective Wittig iodination of the resultant primary hydroxyl group to provide diol (+)-**12**. Next, chemoselective monosilylation of (+)-**12** with TBSCl was accomplished by exploiting a subtle steric difference between its two secondary hydroxyl groups. The remaining secondary hydroxyl group was then pivoylated under forcing conditions to furnish differentially protected pyranose (+)-**13**. Exposure of (+)-**13** to DBU promoted elimination of the primary iodide to generate exocyclic enol ether (+)-**14**, which underwent type-II Ferrier rearrangement upon treatment with catalytic Hg(OCOCF₃)₂.⁷ The resultant β-hydroxy-cyclohexanone was dehydrated to provide (+)-**15**. Following our previous procedures,³ⁱ (+)-**15** was converted to (+)-**16**⁸ and the tertiary C14-OH was ultimately TMS-protected to give annulation acceptor (+)-**9**.


Scheme 3. Synthesis of the AB-/HG-enone (+)-**9**



“Conditions: (a) AcOH/H₂O, 80 °C; (b) PPh₃, I₂, imidazole, PhMe/CH₂Cl₂, RT → 45 °C, 76% (two steps); (c) TBSCl, imidazole, CH₂Cl₂, 0 °C → RT, 99%; (d) PivCl, 4-DMAP, ClCH₂CH₂Cl, 50 °C, 94%; (e) DBU, MeCN, 80 °C, 75%; (f) 30 mol% Hg(OCOCF₃)₂, Me₂CO/H₂O; (g) MsCl, Et₃N, CH₂Cl₂, 0 °C → RT, 74% (two steps); (d) LiHMDS, THF, 0 °C; then TMSOTf, 0 °C → RT, 99%.


Demonstration of a Biomimetic Etherification on a Model ABCD-Ring System. A key transformation in our synthesis plan is a late-stage biomimetic etherification that retrosynthetically symmetrizes hibarimicinone (**2a**) and HMP-P1 (**6**). Consequently, a model ABCD-ring system was first investigated to test the viability of this proposed reaction. Kraus annulation⁹ of cyanophthalide **17**¹⁰ with *ent*-AB-/HG-enone *ent*-**9**⁸ under rigorously oxygen-free conditions gave ABCD-tetracycle (–)-**18** (Scheme 4). Deoxygenation was critical for the success of the annulation, as adventitious oxygen caused decomposition. (–)-**18** was then oxidized with DDQ to the corresponding C-ring quinone, which upon exposure to anhydrous HCl led to clean formation of pentacyclic ether (+)-**20**. This transformation presumably occurs through the intermediacy of *ortho*-quinone methide **19**,¹¹ which is trapped by the proximal acetone

Scheme 5. Synthesis of HMP-Y1 (3a) and atrop-HMP-Y1 (3b) via a Benzyl Fluoride Michael–Claisen Reaction Sequence



“Conditions: (a) Me_2SO_4 , K_2CO_3 , Me_2CO , 98%; (b) $m\text{-CPBA}$, NaHCO_3 , CH_2Cl_2 ; then Na_2CO_3 , MeOH ; (c) NaH , MOMCl , DMF , $0^\circ\text{C} \rightarrow \text{RT}$, 91% (two steps); (d) $t\text{-BuLi}$, TMEDA , THF , $-78 \rightarrow 0^\circ\text{C}$; then FeCl_3 , $0^\circ\text{C} \rightarrow \text{RT}$, 76%; (e) Br_2 , Py , CH_2Cl_2 , 0°C , 91%; (f) $t\text{-BuLi}$, THF , -78°C ; then ClC(O)OMe , $-78^\circ\text{C} \rightarrow \text{RT}$, 89%; (g) LiTMP , THF , -78°C ; then $(\text{BrCF}_2)_2$, -78°C , 62%; (h) TBAT , MeCN , 82°C , 75%; (i) (+)-9, LiTMP , THF , -78°C ; then HMDS , $-78 \rightarrow -35^\circ\text{C}$; then $\text{MgBr}_2\cdot\text{OEt}_2$, $-35 \rightarrow 0^\circ\text{C}$; (j) $\text{CF}_3\text{CH}_2\text{OH}/\text{H}_2\text{O}$, NaHCO_3 , 80°C , 55% (two steps); (k) aq. HF , MeCN/THF , 50°C ; (l) H_2 , $\text{Pd(OH)}_2/\text{C}$, THF ; for **3a**, 59% (two steps); for **3b**, 62% (two steps).

Scheme 4. Synthesis of an ABCD-Pentacyclic Model System



“Conditions: (a) LiHMDS , THF , $-78 \rightarrow 0^\circ\text{C}$, 94%; (b) DDQ , CH_2Cl_2 , -20°C ; (c) HCl , CH_2Cl_2 , 0°C , 69% (two steps).

oxygen with concomitant acetonide cleavage. Notably, this acid-mediated etherification required high dilution in order to avoid formation of (–)-18 and decomposition products, potentially via intermolecular processes.^{11c} We propose that acetonide cleavage is triggered by its proximity to the reactive *ortho*-quinone methide intermediate due to the failure to isolate any acetonide cleavage products that lack the cyclic ether bond. This concept is further justified by later observations on the dimeric system, where only the acetonide of A-ring is cleaved whereas the G-ring acetonide remains intact (vide infra). Overall, the model oxidation-etherification sequence afforded excellent precedence for our subsequent studies.

Development of a Benzyl Fluoride Michael–Claisen Reaction Sequence to Achieve the First Total Synthesis of HMP-Y1 (3a) and atrop-HMP-Y1 (3b). Our synthesis plan for HMP-Y1 (3a) involved a symmetric two-directional double annulation to generate C_2 -symmetric octacycle 7, which could potentially be

desymmetrized through a biomimetic mono-oxidation to access hibarimicinone (2a) and HMP-P1 (6). Such an ambitious double annulation strategy required a flexible synthesis of symmetric biaryl annulation donors in which different substituents at C6/C6' could be introduced, due to the lack of robust annulation sequences to generate naphthols (1-hydroxynaphthalenes rather than 1,4-dihydroxynaphthalenes, i.e., hydroquinones).¹² Our biaryl synthesis began with 5-methylvanillin **21** (Scheme 5), which was converted to trialkoxytoluene **22** in a three step process involving: (1) *O*-methylation, (2) Dakin oxidation followed by in situ formate methanolysis, and (3) MOM protection of the resultant phenol. Next, regioselective *ortho*-lithiation of **22** at C2' and FeCl_3 -mediated oxidative dimerization of the resultant aryllithium species delivered biaryl (±)-23. Carbomethoxy groups were then installed in a two-step sequence involving bromination and lithium–halogen exchange followed by acylation to afford bis-*ortho*-toluate (±)-24.

The reaction kinetics and ultimate success of Michael–Claisen reaction sequences¹⁴ hinges on numerous factors. These include, but are not limited to: (1) the stability and nucleophilicity of the reacting carbanion,¹⁵ (2) the stability of the electrophilic acceptor to the base required to deprotonate the donor,¹⁶ and (3) the steric bulk of the donor (substituents at C6/C6' and the ester side chain) and of the acceptor. Furthermore, the slow step of the tandem reaction sequence will change based on the particular donor and acceptor used. We found that (±)-24 could be deprotonated twice by LiTMP and that the corresponding dianion underwent two-directional bis-Michael–Claisen reaction sequence with various 2-cyclohexenones, including the AB-/HG-enone *ent*-9. However, the slow rate of both the Michael and Claisen reactions¹⁷ of the sequence with sterically encumbered *ent*-9 versus simpler 2-cyclohexenones coupled with the finite lifetime of the dianion of (±)-24 led to very low yields (<10%) of the desired octacyclic dihydronaphthalene products. Attempts to facilitate the Claisen step

of the reaction sequence by utilizing activated ester analogues (i.e., phenyl and 2,2,2-trifluoroethyl) were particularly problematic since the sterically larger activated esters slowed the initial Michael reaction and the dianions were more prone to decomposition. Most importantly, aromatization of the C-/F-rings of the octacyclic products was met with difficulty and led us to consider alternative approaches.¹⁸ Benzyl sulfoxide¹⁹ and benzyl sulfone²⁰ substituted *ortho*-toluates were also evaluated to achieve the desired naphthol annulation with (+)-**9** or *ent*-**9**, but ultimately proved unsuccessful in the context of a two-directional double annulation (*vide infra*).

We next envisaged a benzyl fluoride Michael–Claisen reaction sequence to generate naphthalenes after subsequent dehydrohalogenation.²¹ Although there was no precedence for such a strategy, a benzyl fluoride annulation donor was attractive for several reasons: (1) the electronegative fluorine atom should stabilize the biaryl dianion, (2) the small atomic radius of fluorine should provide minimal steric hinderance to the initial Michael reaction, (3) the strength of C–F bonds would disfavor α -elimination and S_N2 displacement of fluoride, and (4) despite the strength of C–F bonds, elimination of the benzyl fluoride under appropriate conditions could lead to C- and F-ring aromatization.²² The dianion of (\pm)-**24** was brominated with (BrCF₂)₂ to yield the bis-benzyl bromide, which upon heating with TBAT²³ afforded bis-benzyl fluoride (\pm)-**25**. After significant experimentation, the desired protected HMP-Y1 derivatives (–)-**27a** and (+)-**27b**²⁴ were accessed from (+)-**9** and (\pm)-**25** in a two-step procedure involving: (1) a bis-Michael–Claisen reaction sequence promoted by LiTMP and MgBr₂•OEt₂ to afford octacycles **26a** and **26b** and (2) the formal elimination of HF by heating the unpurified reaction product in 2,2,2-trifluoroethanol (TFE) to achieve aromatization of the C- and F-rings and provide atropisomers (–)-**27a** and (+)-**27b**, which were readily separated and carried forward independently. Several features of this sequence deserve comment. As we had hoped, the use of a bis-benzyl fluoride (\pm)-**25** allowed for the initial bis-Michael addition to occur at –78 °C, thus minimizing decomposition of the dianion intermediate and of (+)-**9**. Addition of MgBr₂•OEt₂ mid annulation sequence was critical to promote the final intramolecular Claisen reactions and obviated the need to use an activated ester analogue. This discovery should help expand the substrate scope of the Michael–Claisen reaction sequence. Finally, the unique ability of TFE to promote the desired elimination is presumably due to its ability to strongly hydrogen bond with fluorine, and thus activate it for mild solvolysis. Indeed, use of ethanol in place of TFE only led to trace elimination. The employment of a benzyl fluoride annulation-elimination sequence to generate naphthalene derivatives is without precedence and may prove to be a general method for the synthesis of naphthols.


Global deprotection of (–)-**27a** and (+)-**27b** with aqueous HF followed by hydrogenolysis afforded HMP-Y1 (**3a**) and atrop-HMP-Y1 (**3b**), respectively.²⁵ Heating **3a** or **3b** to 90 °C led to no detectable isomerization about the C2–C2' bond.⁸ With no authentic CD-spectra for natural **3a** available, synthetic **3a** and **3b** were designated based on comparison to the CD spectrum of the glycosylated derivative of **3a**, HMP-Y6.⁸ The axial stereochemistry of HMP-Y1 (**3a**) has not been rigorously determined, although model studies and the CD-spectra of HMP-Y6 and hibarimicinone (**2a**) suggest **3a** possesses the *aR* configuration by the CD exciton chirality method.^{2,26} Additionally, **3a**, **2a**, and hibarimicin A–G are all isolated as single atropisomers.²⁶ We show that the axial stereochemistry of **3a** and **2a** are not the result of thermodynamic equili-

bration (*vide infra*), and thus their biosynthetic relationship also argues that they possess the same relative configuration about the C2–C2' bond. Therefore, since the axial chirality of **2a** was unambiguously determined,⁴ **3a** can be assigned the *aR* configuration.

Biomimetic Mono-Oxidation of Protected HMP-Y1. With a route to HMP-Y1 (**3a**) and atrop-HMP-Y1 (**3b**) established, we next attempted the biomimetic mono-oxidation of protected HMP-Y1 derivatives. We discovered that the desired oxidation of *ent*-**27a** to the C-ring quinone (–)-**29** could be achieved in low yield with CAN (Scheme 6), demonstrating the plausibility of our proposed biomimetic desymmetrizing oxidation. We speculate that the congested biaryl may sterically occlude the approach of oxidants to the otherwise easily oxidized D-/E-ring system,²⁷ allowing oxidation of the more electron-deficient C-/F-rings. Despite this initial success, our attempts to optimize the CAN oxidation were met with difficulty due to bis-oxidation and formation of nitrated byproducts. A survey of other oxidants also proved fruitless.


Nevertheless, with naphthazarin (–)-**29** in hand we next investigated the desired biomimetic etherification reaction. Unfortunately, exposure of (–)-**29** to the optimized conditions developed on our model system led to no observable etherification but rather only rapid MOM group cleavage. A screen of various acids and conditions also proved unsuccessful. The resistance of (–)-**29** to undergo the desired etherification in contrast to the C-ring quinone derivative of (–)-**18** was surprising. Since the major difference between the two systems is the lability of the MOM groups of (–)-**29** relative to the methyl group of (–)-**18**, we postulated that a free phenol at C1' might disfavor either acetonide decomposition or formation of the necessary *ortho*-quinone methide intermediate. This prompted us to replace the MOM group with a more acid-stable protecting group.

Scheme 6. Biomimetic Mono-Oxidation of Protected HMP-Y1.




Additionally, our current biomimetic strategy would inevitably require a late-stage demethylation of the C4'–OMe methyl group. Ideally, one would remove the C4'–OMe methyl group as late in an eventual synthesis of hibarimicin B (**1**) as possible to protect the sensitive and stereochemically labile binaphthyl core (*vide infra*). However, the acidic conditions necessary to effect demethylation would be incompatible with the sensitive 2-deoxy- and 2,3-

Scheme 8. Completion of Hibarimicinone (2a), atrop-Hibarimicinone (2b), and HMP-P1 (6)



Conditions: (a) LiHMDS, THF, $-78 \rightarrow 0^\circ\text{C}$; then KHMDS, $0^\circ\text{C} \rightarrow \text{RT}$, 50–59%; (b) DMTSF, DTBMP, MeCN, $0^\circ\text{C} \rightarrow \text{RT}$; for (–)-35a, 75%; for (+)-35b, 89%; (c) for (–)-35a: DDQ, PhMe, 0°C ; for (+)-35b: DDQ, PhMe, $0^\circ\text{C} \rightarrow \text{RT}$; (d) HCl, $\text{ClCH}_2\text{CH}_2\text{Cl}$, 5°C ; for (–)-37a, 77% (two steps); for (+)-37b, 86% (two steps); (e) aq. HF, MeCN/THF; (f) H_2 , Pd(OH) $_2$ /C, EtOAc; then HCl, MeOH, air; for 2a, 81% (two steps); for 2b, 60% (two steps); (g) aq. pH 7.5 NaH_2PO_4 /NaOH buffer, MeOH, RT; from 2a, 84%; from 2b, 84%.

Scheme 7. Synthesis of Unsymmetrical Biaryl (±)-34 via a Selective Mono-Deprotonation of (±)-24



Conditions: (a) LiTMP, THF, -78°C ; then $(\text{BrCF}_2)_2$, 82%; (b) Pr_2NEt , DMSO, 70°C , 87%; (c) TFA, CH_2Cl_2 , $0^\circ\text{C} \rightarrow \text{RT}$; (d) BCl_3 , CH_2Cl_2 , $-78 \rightarrow 0^\circ\text{C}$; (e) BnBr, K_2CO_3 , DMF, $0 \rightarrow 60^\circ\text{C}$, 94% (three steps); (f) $\text{Me}_2\text{C}(\text{OH})\text{CN}$, Et_3N , CHCl_3 , 97%; (g) LiTMP, THF, -78°C ; then $\text{Ph}(\text{O})_2\text{SSPh}$, 71%.

dideoxyglycosides of 1. The aforementioned reasons prompted us to investigate our alternative strategy for the synthesis of hibarimicinone (2a) and HMP-P1 (6) utilizing an unsymmetrical two-directional annulation reaction with biaryl (±)-34 (Scheme 7).

Synthesis of the Unsymmetrical Biaryl Annulation Donor (±)-34. The unsymmetrical fully substituted biaryl (±)-34 presents unique synthesis challenges that are shared with the hibarimicins; cross-coupling technology to form such sterically hindered biaryls from electron-rich aromatics is limited.^{3d} In contrast, dimerization reactions to form hindered biaryls are robust and reliable (e.g., 22

\rightarrow (±)-23). Thus we imagined that a practical synthesis approach to (±)-34 would necessitate the desymmetrization of (±)-24. A strategy to mono-functionalize (±)-24 involving radical bromination would inevitably result in an inefficient statistical mixture of benzylic bromides. However, we hypothesized that selective mono-deprotonation of (±)-24 would be feasible since the initial carbanion would elevate the pKa of the remaining *ortho*-toluate due to a field effect. Indeed, we found that selective mono-deprotonation of (±)-24 at C6' could be achieved with 1.25 equiv of LiTMP (Scheme 7). The resultant anion (±)-30 was then brominated with $(\text{BrCF}_2)_2$ to give benzyl bromide (±)-31 in 82% yield (Scheme 7). This single element of asymmetry was sufficient to introduce the remaining differential functionality of (±)-34. (±)-31 was oxidized to aldehyde (±)-32,²⁸ which was then converted to tri-benzyl-protected biaryl (±)-33 by (1) acid-promoted removal of the MOM groups, (2) chemoselective cleavage of the C4'–OMe methyl group with BCl_3 , and (3) global reprotection with BnBr. Treatment of (±)-33 with a controlled source of hydrogen cyanide afforded a cyanophthalide intermediate.²⁹ Finally, double deprotonation of this intermediate with LiTMP followed by a short exposure to *S*-phenyl benzenethiosulfonate chemoselectively installed the phenyl sulfide moiety²¹ at C6 to provide biaryl (±)-34. The observed chemoselectivity in this reaction is a result of the much higher reactivity of the *ortho*-toluate anion relative to the cyanophthalide anion.

Completion of Hibarimicinone (2a) and atrop-Hibarimicinone (2b) via an Unsymmetrical Two-Directional Double Annulation. We anticipated that reaction of the lithiated cyanophthalide of (±)-34 with (+)-9 would directly construct the C-ring hydroquinone via a Kraus annulation, and reaction of the lithiated benzyl phenyl sulfide of (±)-34 with a second equivalent of (+)-9 would lead to the F-ring via a Michael–Claisen reaction sequence. We found that the desired transformations could be




Figure 2. (A) Upon standing in acidic methanol (1 M HCl) at RT, hibarimicinone (**2a**) and atrop-hibarimicinone (**2b**) undergo minor interconversion and minimal conversion to HMP-P1 (**6**) (orange HPLC traces). (B) Exposure of **2a** to pH 7.5 aqueous phosphate buffer at RT (blue HPLC traces) or (C) acidic methanol (1 M HCl) at 60 °C (red HPLC traces) resulted in isomerization to **2b** and eventual formation of **6**. See SI for HPLC timecourses for **2b**.

achieved by treating a mixture of (\pm)-**34** and (+)-**9** with LiHMDS followed by subsequent addition of KHMDS mid annulation sequence under rigorously oxygen-free conditions to yield octacycle (–)-**35a** and (+)-**35b** as a ~1.3:1 mixture of atropisomers (Scheme 8). The addition of KHMDS was crucial to facilitate the final intramolecular Claisen reaction to construct the F-ring.³⁰ At this stage, atropisomers (–)-**35a** and (+)-**35b** were separated and carried forward independently. Elimination of the C6-benzylic phenyl sulfide was accomplished with dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSE) to yield binaphthalenes (–)-**36a** and (+)-**36b**. It is worth reiterating at this point that the corresponding C6-benzyl sulfoxide and sulfone derivatives of (\pm)-**34** ultimately proved unsuccessful in a two-directional annulation,³¹ highlighting the difficulty to achieve naphthol annulations in the context of complex molecule synthesis. To the best of our knowledge, this is the first example of a benzyl sulfide Michael–Claisen reaction sequence to generate naphthalenes, and together with the benzyl fluoride Michael–Claisen reaction sequence reported offer two new alternatives to approach challenging naphthol annulations.

Oxidation of (–)-**36a** and (+)-**36b** with DDQ produced the corresponding C-ring quinones. Exposure of the respective quinones to anhydrous HCl promoted the desired biomimetic etherification to yield nonacycles (–)-**37a** and (+)-**37b**. This successful etherification of the benzyl protected naphthazarins, in contrast to MOM-protected (–)-**29**, confirmed our suspicion that the nature of the C1'-phenol has far-reaching stereoelectronic effects on this system. With the complete skeletons of **2a** and **2b** in hand, all that remained to complete the syntheses was global deprotection and oxidation of the D-ring. Deprotection of the acid-labile protecting groups was accomplished upon exposure to HF. Finally, the benzyl groups were removed via hydrogenolysis, and after addition of acidic methanol, filtering, and exposure to air, hibarimicinone (**2a**) and atrop-hibarimicinone (**2b**) were formed. All of the spectroscopic data for **2a** and **2b** match those reported^{4,8,26} and thereby confirmed the structure of **2b**.

Discovery of a pH-Dependent Rotational Barrier About the C2–C2' Bond in Hibarimicinone (2a) and atrop-Hibarimicinone (2b). The addition of acidic methanol prior to aerobic oxidation was crucial to prevent isomerization between **2a** and **2b** and formation of HMP-P1 (**6**).^{25,32} Upon prolonged handling or standing at ambient temperatures in acidic methanol (1 M HCl), we observed minor interconversion between **2a** and **2b** minimal formation of **6** (Figure 2A). However, simple exposure of **2a**

and **2b**, independently, to pH 7.5 buffered methanol led to the formation of **6** in 84% yield in both cases (Scheme 8). Monitoring these transformations by HPLC revealed that nearly complete isomerization about the C2–C2' bond (**2a** \leftrightarrow **2b**) had occurred within 4 hours while formation of **6** was almost complete after 24 hours (Figure 2B).⁸ Together, these observations suggest that the rotational barriers about C2–C2' for **2a** and **2b** are pH-dependent.




Figure 3. A proposed model to explain the pH-dependent rotational barrier about the C2–C2' bond of **2a** and **2b**. Only the CDEF-ring system is depicted for brevity.

These findings are particularly interesting owing to prior observations that heating **2a** in neutral methanol at 60 °C leads to nearly complete interconversion to **2b** in 30 minutes and ultimately complete cyclization to yield **6** after 90 minutes.^{11,2,26} However, we found that heating either **2a** or **2b** to 60 °C in acidic methanol (1 M HCl) led to only partial interconversion between **2a** and **2b** and minor conversion to **6** after 90 minutes (Figure 2C). This suggests that the observed rapid rotation at 60 °C in neutral methanol has less to do with providing the necessary thermal energy to surpass the intrinsic activation barrier about C2–C2' in the uncharged forms of **2a/2b** (**38a/38b** in Figure 3), but rather enables access to the deprotonated form of **2a** and **2b** (**39a/39b** in Figure 3) via inter- or intramolecular proton transfer. Rapid interconversion between **37a** and **37b** can then follow through a transition state that is stabilized by π -electron overlap,^{1b,33} as depicted in cross-conjugated resonance structures **40a** and **40b**. Consequently, variables that affect the equilibrium between **38a** and **39a**, and **38b** and **39b** will affect the rate of isomerization. The addition of acid to the

media inhibits access to species **39a** and **39b** by driving the equilibrium toward **38a** and **38b**, and thus disfavors isomerization. In contrast, heat (60 °C) should promote equilibration between the protonation states and thus facilitate isomerization. Our discovery of the pH-dependent barrier demonstrates the delicate nature of the C2–C2' which must be accommodated in an eventual synthesis of hibarimicin B (**1**).³²

Conclusion

Enantioselective syntheses of hibarimicinone (**2a**) and atrop-hibarimicinone (**2b**), and the first total syntheses of HMP-Y1 (**3a**), atrop-HMP-Y1 (**3b**), and HMP-P1 (**6**) have been accomplished. The complete carbon skeleton of each natural product was assembled via a convergent two-directional annulation strategy. The use of a racemic biaryl in conjunction with the two-directional annulation strategy enabled both atropisomers of the natural products to be separately constructed and fully characterized, thus providing the first reported full characterization of **2b**, **3a**, **3b**, and **6**. Additionally during the pursuit of this annulation strategy, we encountered numerous challenges when conducting naphthol annulation reactions. Consequently, we developed two valuable Michael–Claisen reaction sequences to construct complex naphthols that might find use as general methods. The mild conditions needed to dehydrohalogenate the benzyl fluoride intermediates are particularly noteworthy given the strength of C–F bonds.

The plausibility of our proposed biosynthesis was also validated by the demonstration that a desymmetrizing mono-oxidation of the C-ring can be conducted on protected HMP-Y1 derivatives. Over-oxidation to the bis-C-/F-ring quinone was also observed, but natural products corresponding to such a double oxidation have not been isolated in nature or during mutagenesis studies. This perhaps suggests that an enzyme mediates this key biosynthetic transformation, but how **3a** is only mono-oxidized remains unclear.

After the key two-directional annulations, only three and five steps were needed to complete HMP-Y1 (**3a**) and hibarimicinone (**2a**), respectively. In the case of **2a**, these steps include a biomimetic etherification to install the B-ring cyclic ether via an *ortho*-

quinone methide intermediate. The success of this reaction required an acid-stable protecting group on the C1'-phenol owing to subtle yet far-reaching stereoelectronic effects imparted by the naphthazarin-naphthalene system. The peculiarities and sensitivity of this system are also highlighted by our discovery of the pH-dependent rotational barrier about the C2–C2' bond. These particular observations provide crucial information that will facilitate an eventual synthesis of hibarimicin B (**1**).

Lastly, the intermediate (–)-**37a** will be highly useful in an eventual total synthesis of **1**; it is suitably protected with orthogonal protecting groups to allow for the sequential installation of the 2-deoxy- and 2,3-dideoxyglycosides prior to deprotection of the sensitive binaphthyl core of the molecule. Future studies toward the total synthesis of **1** will be reported in due course.

ASSOCIATED CONTENT

Supporting Information. Experimental procedures, spectroscopic data, and copies of CD, UV–vis, ¹H and ¹³C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

shair@chemistry.harvard.edu

Funding Sources

No competing financial interests have been declared. We acknowledge financial support from NIH (R01GM090068). B.B.L. acknowledges a NSF Predoctoral Fellowship and Bristol-Myers Squibb. B.C.M. acknowledges Eli Lilly and AstraZeneca.

ACKNOWLEDGMENT

We thank Prof.'s Y. Igarashi, H. Hori, and G. Sulikowski for communication regarding atropisomerism and for providing authentic spectroscopic data. B.B.L. acknowledges Amy S. Lee for helpful discussions.

REFERENCES

- (1) (a) Uehara, Y.; Li, P. M.; Fukazawa, H.; Mizuno, S.; Nihei, Y.; Nishio, M.; Hanada, M.; Yamamoto, C.; Furumai, T.; Oki, T. *J. Antibiot.* **1993**, *46*, 1306–1308. (b) Hori, H.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *Tetrahedron Lett.* **1996**, *37*, 2785–2788. (c) Kajiura, T.; Furumai, T.; Igarashi, Y.; Hori, H.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *J. Antibiot.* **1998**, *51*, 394–401. (d) Hori, H.; Igarashi, Y.; Kajiura, T.; Furumai, T.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *J. Antibiot.* **1998**, *51*, 402–417. (e) Hori, H.; Kajiura, T.; Igarashi, Y.; Furumai, T.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *J. Antibiot.* **2002**, *55*, 46–52. (f) Kajiura, T.; Furumai, T.; Igarashi, Y.; Hori, H.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *J. Antibiot.* **2002**, *55*, 53–60. (g) Igarashi, Y.; Kajiura, T.; Furumai, T.; Hori, H.; Higashi, K.; Ishiyama, T.; Uramoto, M.; Uehara, Y.; Oki, T. *J. Antibiot.* **2002**, *55*, 61–70. (h) Cho, S. I.; Fukazawa, H.; Honma, Y.; Kajiura, T.; Hori, H.; Igarashi, Y.; Furumai, T.; Oki, T.; Uehara, Y. *J. Antibiot.* **2002**, *55*, 270–278. (i) Hori, H.; Igarashi, Y.; Kajiura, T.; Sato, S.; Furumai, T.; Higashi, K.; Ishiyama, T.; Uehara, Y.; Oki, T. *Tennen Yuki Kagobutsu Toronkai Koen Yoshishu* **2004**, *46*, 49–54.
- (2) Romaine, I. M.; Hempel, J. E.; Shanmugam, G.; Hori, H.; Igarashi, Y.; Polavarapu, P. L.; Sulikowski, G. A. *Org. Lett.* **2011**, *13*, 4538–4541.
- (3) For studies towards the hibarimicins or their related natural products, see: (a) Lee, C.-S.; Audelo, M. Q.; Reibenpies, J.; Sulikowski, G. A. *Tetrahedron* **2002**, *58*, 4403–4409. (b) Maharoof, U. S.; Sulikowski, G. A. *Tetrahedron Lett.* **2003**, *44*, 9021–9023. (c) Kim, K.; Maharoof, U. S.; Rauschel, J.; Sulikowski, G. A. *Org. Lett.* **2003**, *5*, 2777–2780. (d) Narayan, S.; Roush, W. R. *Org. Lett.* **2004**, *6*, 3789–3792. (e) Lambert, W. T.; Roush, W. R. *Org. Lett.* **2005**, *7*, 5501–5504. (f) Lee, W. D.; Kim, K.; Sulikowski, G. A. *Org. Lett.* **2005**, *7*, 1687–1689. (g) Li, J.; Todaro, L. J.; Mootoo, D. R. *Org. Lett.* **2008**, *10*, 1337–1340. (h) Li, J.; Todaro, L.; Mootoo, D. R. *Eur. J. Org. Chem.* **2011**, 6281–6287. (i) Milgram, B. C.; Liao, B. B.; Shair, M. D. *Org. Lett.* **2011**, *13*, 6436–6439.
- (4) Tatsuta, K.; Fukuda, T.; Ishimori, T.; Yachi, R.; Yoshida, S.; Hashimoto, H.; Hosokawa, S. *Tetrahedron Lett.* **2012**, *53*, 422–425.
- (5) The use of a benzyl group was a strategic concession to protect the sensitive core of **1** up until the last step of an eventual synthesis of **1**.
- (6) For other examples of two-directional double annulation reactions, see: (a) Hauser, F. M.; Gauuan, P. J. *Org. Lett.* **1999**, *1*, 671–672. (b) Ref. 2. (c) Ref. 4, and references therein.
- (7) Ferrier, R. J. *J. Chem. Soc., Perkin Trans. 1* **1979**, 1455–1458.
- (8) See SI for full details.
- (9) G. A. Kraus, H. Sugimoto, *Tetrahedron Lett.* **1978**, *19*, 2263–2266.

(10) Wendt, J. A.; Gauvreau, P. J.; Bach, R. D. *J. Am. Chem. Soc.* **1994**, *116*, 9921–9926.

(11) For related transformations utilizing *ortho*-quinone methides, see: (a) Ref. 4. (b) Hart, D. J.; Huang, H.-C. *J. Am. Chem. Soc.* **1988**, *110*, 1634–1635. (c) Nicolaou, K. C.; Lim, Y. H.; Piper, J. L.; Papageorgiou, C. *J. Am. Chem. Soc.* **2007**, *129*, 4001–4013.

(12) For reviews, see: (a) Mal, D.; Pahari, P. *Chem. Rev.* **2007**, *107*, 1892–1918. (b) Rathwell, K.; Brimble, M. A. *Synthesis* **2007**, *5*, 643–662.

(13) 5-Methylvanillin (**S15**) was prepared from vanillin in two steps on multigram scale following a literature procedure: Sinhababu, A. K.; Borchardt, R. T. *Syn. Comm.* **1983**, *13*, 677–683.

(14) (a) For other uses of Michael–Claisen reaction sequences to construct naphthalene derivatives, see: Sun, C.; Wang, Q.; Brubaker, J. D.; Wright, P. M.; Lerner, C. D.; Noson, K.; Charest, M.; Siegel, D. R.; Wang, Y.-M.; Myers, A. G. *J. Am. Chem. Soc.* **2008**, *130*, 17913–17927, and references therein. (b) For a related approach to **3a**, see ref. 2.

(15) (a) *ortho*-Toluate and related carbanions will suffer from competitive bimolecular self-condensation reactions with the ester moiety if the Michael addition is not fast enough. For an interesting discussion on the stability of *ortho*-toluate and related carbanions, see Brubaker, J. D. Ph.D. Thesis, Harvard University, 2007 and references therein. (b) In the case of a single annulation process, the instability of the deprotonated annulation donor can often be partially circumvented through the use of excess donor. However, due to the inherent stoichiometry of the two-directional double annulation, the biaryl donor is used as the limiting reactant and thus the stability of its dianion is critical to the success of the reaction.

(16) We observed that *ent*-**9** is stable to LiTMP and LDA at -78°C , and LiHMDS at 0°C in THF. At higher respective temperatures for prolonged reaction times, significant decomposition occurred.

(17) Simple 2-cyclohexenones will undergo the Michael addition within seconds at -78°C and eventual Claisen reaction at -10°C with the *ortho*-toluate carbanion corresponding to the D-/E-ring. In contrast, *ent*-**9** underwent Michael addition after approximately 1 hour and the Claisen reaction was never driven to completion with the dianion of (\pm)-**24**.

(18) DDQ or PhSeCl with pyridine could successfully be employed to aromatize dihydronaphthalenes of simple BCD-ring model systems but proved unsuccessful on binaphthyl systems.

(19) (a) Hauser, F. M.; Rhee, R. P. *J. Org. Chem.* **1978**, *43*, 178–180. (b) Lee, H. G.; Ahn, J.-Y.; Lee, A. S.; Shair, M. D. *Chem. Eur. J.* **2010**, *16*, 13058–13062.

(20) (a) Wildeman, J.; Borgen, P. C.; Pluim, H. *Tetrahedron Lett.* **1978**, *25*, 2213–2216. (b) Huang, X.; Xue, J. *J. Org. Chem.* **2007**, *72*, 3965–3968.

(21) Benzyl phenylsulfide substituted *ortho*-toluates were concurrently found to be useful partners for naphthol annulations and were ultimately employed in our synthesis of **2a** and **6** due to the inability to incorporate a benzyl fluoride at C6 of (\pm)-**34**.

(22) Bitha, P.; Hlavka, J. J.; Boothe, J. H. *J. Med. Chem.* **1970**, *13*, 89–92.

(23) Pilcher, A. S.; Ammon, H. L.; DeShong, P. *J. Am. Chem. Soc.* **1995**, *117*, 5166–5167.

(24) (a) For brevity, each atropisomer is depicted as a single structure lacking stereochemistry about the C2–C2' bond. See SI for full details. (b) The regioisomer of the enolized 1,3-diketone is arbitrarily depicted.

(25) No NMR or CD spectra for **3a** and **6** have been previously recorded according to ref. 26. See SI for full details.

(26) Described in a personal communication with Professor H. Hori and Professor Y. Igarashi.

(27) (a) Preferential oxidation of the D-ring occurs in simpler BCD-ring model systems. (b) The ^1H NMR signal of the methoxymethyl groups of *ent*-**27a** and *ent*-**27b** are shifted over 0.6 ppm up-field relative to the corresponding monomer, suggesting that they are positioned over the naphthyl ring systems and subject to anisotropic magnetic field effects.

(28) Kornblum, N.; Jones, W. J.; Anderson, G. J. *J. Am. Chem. Soc.* **1959**, *81*, 4113–4114.


(29) Sakulsombat, M.; Angelin, M.; Ramström, O. *Tetrahedron Lett.* **2010**, *51*, 75–78.

(30) Kummer, D. A.; Li, D.; Dion, A.; Myers, A. G. *Chem. Sci.* **2011**, *2*, 1710–1718.

(31) The small coupling constant between the C6' and C7' hydrogen atoms of ($-$)-**35a** and ($+$)-**35b** suggest a *syn* relationship of the hydrogen atoms with respect to the ring system. This relative stereochemistry would preclude *syn*-elimination to aromatize the F-ring. Indeed, one diastereomer of the corresponding sulfoxide of (\pm)-**34** underwent two-directional annulation but failed to eliminate to aromatize the F-ring.

(32) The carbohydrates of the hibarimicin natural products are cleaved with acidic methanol (1 M HCl, 30°C). These conditions are similar to those we employ during the benzyl deprotection and oxidation of ($-$)-**37a** and ($+$)-**37b**. However, milder acidic conditions (i.e., aq. pH 3.5 phosphate buffer) in methanol may potentially be substituted during the analogous deprotection and oxidation of **1** since these conditions are employed in the HPLC purification of **1** and hibarimicin related natural products. See ref 1f–g for the conditions used for carbohydrate cleavage and purification of the hibarimicin natural products.

(33) Eliel, E. L.; Wilen, S. H. *Stereochemistry of Organic Compounds*; John Wiley & Sons, Inc.: New York, 1994.



Hibarimicin Aglycons: HMP-Y1, Hibarimicinone, and HMP-P1